RET/MET Multiplex Mutation Screening Kit

The RET gene is closely related to cell growth, the occurrence of many human tumors, and belongs to an important proto-oncogene. The activated RET protein participates in the proliferation, apoptosis, and invasion of different tumor cells through a variety of signal pathways and affects the growth and development of tumor cells.

MET is a receptor tyrosine kinase, which is abnormally activated in tumor cells to promote tumor cell survival, proliferation and invasion. MET gene mutations include overexpression, amplification, exon 14 skipping mutations, and rarer MET rearrangements.

Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.

Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.